Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm lomitapide study in pediatric homozygous familial hypercholesterolemia
2014-003806-33Phase 3Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lomitapide in homozygous familial hypercholesterolemia (HoFH), sponsored by Aegerion Pharmaceuticals. Primary endpoint: Mean percent change in LDL-C from baseline at Week 24. Started Mar 2016; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2014-003806-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003806-33.